Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 689 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 391 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 551 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 690 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 367 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 289 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 340 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 432 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen | |
BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
06.09.24 | BenevolentAI Notice of Interim Results | 420 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months... ► Artikel lesen | |
04.07.24 | BenevolentAI: Appointment of Adviser | 416 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the... ► Artikel lesen | |
03.07.24 | BenevolentAI: Leadership Team Change | 484 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 5,210 | 0,00 % | Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? | ||
ABCELLERA BIOLOGICS | 3,155 | +6,73 % | AbCellera-Aktionäre genehmigen Vorstandswahl und Wirtschaftsprüfer | ||
ANAVEX LIFE SCIENCES | 7,806 | +1,19 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
VERACYTE | 23,000 | +0,88 % | Veracyte, Inc.: Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 | Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40th Annual European Association of Urology Congress (EAU25)... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,215 | -0,58 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside | ||
ASCLETIS PHARMA | 0,965 | +1,58 % | ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIRST PARTICIPANTS WITH OBESITY OR OVERWEIGHT DOSED IN A U.S. 13-WEEK PHASE IIA STUDY ... | ||
BIOMEA FUSION | 1,670 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights | Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients... ► Artikel lesen | |
RELAY THERAPEUTICS | 3,600 | +1,98 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 | Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Data continue to support... ► Artikel lesen | |
JASPER THERAPEUTICS | 6,830 | 0,00 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria | 11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower... ► Artikel lesen | |
ABSCI | 2,700 | 0,00 % | Absci Corporation: Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease | Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing... ► Artikel lesen | |
LANTERN PHARMA | 3,190 | 0,00 % | Lantern Pharma's LP-184 shows promise for pediatric brain cancer | ||
Y-MABS THERAPEUTICS | 4,250 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments | Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines... ► Artikel lesen | |
QIAGEN | 40,740 | -1,31 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
NUVALENT | 80,50 | 0,00 % | Goldman Sachs nimmt Nuvalent-Aktie mit Kaufempfehlung in die Bewertung auf | ||
EVOTEC | 7,350 | +1,38 % | Übernahmefieber! BioTech und Künstliche Intelligenz beflügelt Evotec, NetraMark Holdings, NovoNordisk und Bayer | Derzeit erlebt der Biotech-Sektor eine spannende Transformation: Denn Big Data und Künstliche Intelligenz verändern in rasanter Art und Weise, wie neue Medikamente entdeckt, entwickelt und getestet... ► Artikel lesen |